Last edition
News about "Kineticos AMR Accelerator Fund I "
Kineticos Launches Kinvard Bio to Power Next-Gen Antibiotics
KAMRA I is dedicated to combating antimicrobial resistance (AMR) by investing in, creating, and supporting companies that are developing disruptive solutions to address this critical public health issue.
Kineticos AMR Accelerator Fund I | 25/02/2025 | By Aishwarya | 224
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members